Leinco Technologies, Inc.'s Anti-SARS-CoV-2 Nucleocapsid (N) - 500 µg monoclonal antibody. The Anti-SARS-CoV-2 Nucleocapsid (N) - 500 µg Antibody was generated using N as the antigen. It reacts with 2019-nCoV, Corona Virus, Coronavirus, COVID-19, SARS-CoV-2, and Virus. This antibody has been shown to work in applications such as: EIA, Immunoassay, ELISA, Immunohistochemistry, and Western Blot.